Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry
ACCURACY;
ARTICLE;
CALIBRATION;
DRUG DETERMINATION;
DRUG MONITORING;
DRUG RETENTION;
ELECTROSPRAY MASS SPECTROMETRY;
FREEZE THAWING;
HUMAN;
LIQUID CHROMATOGRAPHY;
PLASMA;
PRIORITY JOURNAL;
ROOM TEMPERATURE;
SINGLE DRUG DOSE;
SOLID PHASE EXTRACTION;
TANDEM MASS SPECTROMETRY;
VALIDATION STUDY;
BLOOD;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
REPRODUCIBILITY;
STANDARD;
ULTRAVIOLET SPECTROPHOTOMETRY;
ANALGESICS, OPIOID;
CHROMATOGRAPHY, HIGH PRESSURE LIQUID;
HUMANS;
INDICATORS AND REAGENTS;
MORPHINANS;
OXYCODONE;
OXYMORPHONE;
REFERENCE STANDARDS;
REPRODUCIBILITY OF RESULTS;
SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;
SPECTROPHOTOMETRY, ULTRAVIOLET;
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites
Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79:461-479.
Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998;64:603-611.
Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection
Smith MT, Watt JA, Mapp GP, et al. Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection. Ther Drug Monit. 1991;13:126-130.
Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high performance-liquid chromatography
Cheremina O, Bachmakov I, Neubert A, et al. Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high performance-liquid chromatography. Biomed Chromatogr. 2005; 19:777-782.
Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children
Kokki H, Rasanen I, Reinikainen M, et al. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinetic. 2004;43:613-622.
Quantitative contribution of CYP2D6 and CYP3A4 to oxycodone metabolism in human liver and intestinal microsomes
Lalovic B, Phillips B, Risler L, et al. Quantitative contribution of CYP2D6 and CYP3A4 to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32:447-454.
The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone, and noroxycodone in Ringer solution, rat plasma and rat brain tissue
Boström E, Jansson B, Hammarlund-Udenaes M, et al. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone, and noroxycodone in Ringer solution, rat plasma and rat brain tissue. Rapid Commun Mass Spectrom. 2004;18:2565-2576.
Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry
Edwards SR, Smith MT. Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr B. 2005;814:241-249.
A rapid and sensitive highperformance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma
Dawson M, Fryirs B, Kelly T, et al. A rapid and sensitive highperformance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma. J Chromatogr Sci. 2002;40:40-44.
FDA Guidance, CDER, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine (CVM). Guidance for the Industry. Bioanalytical Method Validation. May 2001. Available at: www.fda.gov/ cder/guidance.
FDA Guidance, CDER, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine (CVM). Guidance for the Industry. Bioanalytical Method Validation. May 2001. Available at: www.fda.gov/ cder/guidance.
12
33645804611
Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism
Lee H-K, Lewis LD, Tsongalis GJ, et al. Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta. 2006;367:196-200.
